Lv61
2840 积分 2022-12-19 加入
Time for a paradigm shift in immunotherapy-based BCMA/CD3 bispecific drug development in multiple myeloma
8天前
已完结
Supportive care for systemic amyloidosis: International Society of Amyloidosis (ISA) expert panel guidelines
2个月前
已完结
Up-Front Treatment of Elderly (Age ≥75 Years) and Frail Patients With Multiple Myeloma
5个月前
已关闭
Optimizing drug therapies in cardiac amyloidosis
5个月前
已完结
Cardiovascular Complications and Their Association With Short- and Long-Term Outcomes in Patients With Multiple Myeloma and Lymphoma Undergoing Chimeric Antigen Receptor T-Cell Therapy
5个月前
已完结
Administration of teclistamab in four patients with multiple myeloma requiring hemodialysis
5个月前
已完结
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial
5个月前
已完结
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
5个月前
已完结
A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients with Relapsed and Refractory Multiple Myeloma
5个月前
已完结
Teclistamab for relapsed refractory multiple myeloma patients on dialysis
6个月前
已完结
皖公网安备34019202002308
